CAS NO: | 1263373-43-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | NVP-2 is a potent and selective ATP-competitivecyclin dependent kinase9 (CDK9)probe, inhibits CDK9/CycT activity with anIC50of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases withIC50values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cellapoptosis.[1] | ||||||||||||||||||||||||||||||||
IC50& Target |
| ||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | NVP-2 has an anti-proliferation of leukemia cells, inhibits KOPT-K1, Jurkat, P12-ICHIKAWA, DU.528, MOLT 16, HSB-2, PF-382, SKW-3, SUP-T11, DND-41 and HPB-ALL cells with IC50values of 0.1688 μM, 0.1233 μM,0.5736 μM,0.1575 μM, 0.1620 μM,0.1585 μM, 0.1808 μM, 0.2589 μM, 0.0918 μM and 0.3023 μM, respectively[1].NVP-2 (250 nM-1 μM; 6 hours) engages CDK9 in wildtype and CRBN–/– MOLT4 cells at all concentrations, while CDK2 and CDK7 are unaffected[1].NVP-2 (0-10 nM; 72 hours) exhibits CRBN-dependent anti-proliferative and pro-apoptotic effects in MOLT4 cells, displays an IC50value of 9 nM[1].NVP-2 (250 nM; 24 hours) induces cell apoptosis in MOLT4 cells, upregulates caspase-3 and γH2A.X expression. However, while the compound washout significantly reduces the degree of apoptosis induced by NVP-2[1]. Cell Viability Assay[1]
Western Blot Analysis[1]
Apoptosis Analysis[1]
Cell Proliferation Assay[1]
| ||||||||||||||||||||||||||||||||
分子量 | 513.07 | ||||||||||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||||||||||
Formula | C27H37ClN6O2 | ||||||||||||||||||||||||||||||||
CAS 号 | 1263373-43-8 | ||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(194.91 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|